| Literature DB >> 35831378 |
Yasuhiro Suzuki1, Hiroaki Suzuki2, Tatsuya Ishikawa3, Yasunori Yamada3, Shigeru Yatoh4, Yoko Sugano4, Hitoshi Iwasaki4, Motohiro Sekiya4, Naoya Yahagi4, Yasushi Hada5, Hitoshi Shimano4,6,7,8.
Abstract
We aimed to investigate the status of falls and to identify important risk factors for falls in persons with type 2 diabetes (T2D) including the non-elderly. Participants were 316 persons with T2D who were assessed for medical history, laboratory data and physical capabilities during hospitalization and given a questionnaire on falls one year after discharge. Two different statistical models, logistic regression and random forest classifier, were used to identify the important predictors of falls. The response rate to the survey was 72%; of the 226 respondents, there were 129 males and 97 females (median age 62 years). The fall rate during the first year after discharge was 19%. Logistic regression revealed that knee extension strength, fasting C-peptide (F-CPR) level and dorsiflexion strength were independent predictors of falls. The random forest classifier placed grip strength, F-CPR, knee extension strength, dorsiflexion strength and proliferative diabetic retinopathy among the 5 most important variables for falls. Lower extremity muscle weakness, elevated F-CPR levels and reduced grip strength were shown to be important risk factors for falls in T2D. Analysis by random forest can identify new risk factors for falls in addition to logistic regression.Entities:
Mesh:
Year: 2022 PMID: 35831378 PMCID: PMC9279484 DOI: 10.1038/s41598-022-15224-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flowchart of selection of study participants.
Characteristics of participants.
| All | Fallers | Non-fallers | ||
|---|---|---|---|---|
| Age (y) | 62 (49, 68) | 63 (54, 69) | 62 (48, 68) | 0.254 |
| Female sex, n (%) | 97 (42.9) | 26 (59.0) | 71 (39.0) | 0.016 |
| Duration of diabetes (y) | 10 (2, 16) | 11 (3, 20) | 9 (2, 15) | 0.070 |
| Height (m) | 1.61 (1.55, 1.68) | 1.60 (1.53, 1.65) | 1.62 (1.55, 1.70) | 0.171 |
| Body weight (kg) | 69.8 ± 17.7 | 70.7 ± 19.0 | 69.6 ± 17.3 | 0.692 |
| Body mass index (kg/m2) | 26.5 ± 5.6 | 27.4 ± 6.0 | 26.3 ± 5.4 | 0.281 |
| Fasting plasma glucose (mmol/l) | 8.9 (7.3, 10.9) | 9.4 (7.8, 11.1) | 8.9 (7.2, 10.8) | 0.279 |
| Fasting serum C-peptide (nmol/l) | 0.5 (0.4, 0.8) | 0.7 (0.4, 0.9) | 0.5 (0.3, 0.7) | 0.032 |
| HbA1c (%) | 9.7 ± 1.9 | 9.5 ± 1.8 | 9.8 ± 1.9 | 0.399 |
| HbA1c (mmol/mol) | 83 ± 20 | 80 ± 20 | 83 ± 21 | |
| Total cholesterol (mmol/l) | 4.8 ± 1.1 | 4.7 ± 0.8 | 4.8 ± 1.1 | 0.408 |
| LDL-cholesterol (mmol/l) | 2.8 ± 0.8 | 2.8 ± 0.7 | 2.8 ± 0.8 | 0.788 |
| HDL-cholesterol (mmol/l) | 1.2 (1.0, 1.4) | 1.2 (1.0, 1.4) | 1.2 (1.0, 1.4) | 0.682 |
| Triglycerides (mmol/l) | 1.4 (1.0, 2.0) | 1.3 (1.1, 2.0) | 1.5 (1.0, 2.0) | 0.487 |
| Creatinine (µmol/l) | 68.2 ± 43.4 | 85.9 ± 75.6 | 63.9 ± 29.8 | 0.064 |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 83 (66, 99) | 73 (53, 93) | 85 (70, 101) | 0.085 |
| Urinary albumin excretion (mg/day) | 10.4 (5.2, 31.6) | 13.6 (6.0, 39.6) | 10.2 (5.1, 25.7) | 0.692 |
| Diabetic polyneuropathy, n (%) | 64 (28.3) | 16 (36.4) | 48 (26.4) | 0.187 |
| Impaired vibratory sensation, n (%) | 53 (23.5) | 16 (36.4) | 37 (20.3) | 0.024 |
| Cardiac autonomic neuropathy, n (%) | 83 (36.7) | 19 (43.2) | 64 (35.2) | 0.322 |
| Nephropathy, n (%) | 66 (29.2) | 16 (32.4) | 50 (27.5) | 0.244 |
| Retinopathy, n (%) | 16 (7.1) | 7 (15.9) | 9 (4.9) | 0.011 |
| baPWV (cm/s) | 1636 ± 354 | 1656 ± 363 | 1631 ± 353 | 0.680 |
| Coronary artery disease, n (%) | 16 (7.1) | 2 (4.5) | 14 (7.7) | 0.465 |
| Stroke, n (%) | 12 (5.3) | 5 (11.4) | 7 (3.8) | 0.046 |
| Peripheral arterial disease, n (%) | 3 (1.3) | 1 (2.3) | 2 (1.1) | 0.538 |
Data are mean ± SD or median (25th, 75th). LDL, low-density lipoprotein; HDL, high-density lipoprotein; baPWV, brachial-ankle pulse wave velocity.
Medications administered to study participants.
| All | Fallers | Non-fallers | ||
|---|---|---|---|---|
| Sulfonylureas | 54 (23.9) | 12 (27.3) | 42 (23.1) | 0.558 |
| Glinides | 6 (2.7) | 2 (4.5) | 4 (2.2) | 0.385 |
| Biguanides | 118 (52.2) | 22 (50.0) | 96 (52.7) | 0.743 |
| SGLT2 inhibitors | 23 (10.2) | 5 (11.4) | 18 (9.9) | 0.772 |
| α-glucosidase inhibitors | 22 (9.7) | 5 (11.4) | 17 (9.3) | 0.685 |
| Thiazolidinediones | 12 (5.3) | 4 (9.1) | 8 (4.4) | 0.213 |
| DPP-4 inhibitors | 112 (49.6) | 25 (56.8) | 87 (47.8) | 0.283 |
| GLP-1 receptor agonists | 12 (5.3) | 4 (9.1) | 8 (4.4) | 0.213 |
| Insulin | 111 (49.1) | 20 (45.5) | 91 (50.0) | 0.588 |
| Antihyperlipidemic agents | 90 (39.8) | 17 (38.6) | 73 (40.1) | 0.858 |
| Antihypertensive agents | 88 (38.9) | 20 (45.5) | 68 (37.4) | 0.323 |
| Sulfonylureas | 33 (14.6) | 10 (22.7) | 23 (12.6) | 0.089 |
| Glinides | 6 (2.7) | 0 (0) | 6 (3.3) | 0.222 |
| Biguanides | 150 (66.4) | 28 (63.6) | 122 (67.0) | 0.669 |
| SGLT2 inhibitors | 21 (9.3) | 3 (6.8) | 18 (9.9) | 0.529 |
| α-glucosidase inhibitors | 20 (8.8) | 4 (9.1) | 16 (8.8) | 0.950 |
| Thiazolidinediones | 15 (6.6) | 4 (9.1) | 11 (6.0) | 0.466 |
| DPP-4 inhibitors | 109 (48.2) | 23 (52.3) | 86 (47.3) | 0.550 |
| GLP-1 receptor agonists | 24 (10.6) | 7 (15.9) | 17 (9.3) | 0.204 |
| Insulin | 105 (46.5) | 17 (38.6) | 88 (48.4) | 0.246 |
| Antihyperlipidemic agents | 90 (39.8) | 17 (38.6) | 73 (40.1) | 0.858 |
| Antihypertensive agents | 80 (35.4) | 18 (40.9) | 62 (34.1) | 0.394 |
SGTL2, sodium-glucose co-transporter 2; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1.
Physical activity, body composition and physical capabilities of participants.
| All | Fallers | Non-fallers | ||
|---|---|---|---|---|
| Physical activity | ||||
| Steps (steps/d) | 7002 ± 3662 | 7593 ± 5510 | 6859 ± 3057 | 0.398 |
| MVPA time (min/d) | 13.9 (7.5, 26.0) | 11.4 (6.1, 24.4) | 14.4 (7.7, 26.0) | 0.313 |
| Body composition | ||||
| Skeletal muscle percentage (%) | 37 ± 5 | 36 ± 5 | 38 ± 5 | 0.013 |
| Body fat percentage (%) | 33 ± 9 | 35 ± 9 | 32 ± 9 | 0.058 |
| Skeletal muscle mass index (kg/m2) | 8.3 ± 1.4 | 8.1 ± 1.4 | 8.3 ± 1.4 | 0.379 |
| Muscle strength | ||||
| Knee extension strength (Nm/kg) | 1.49 ± 0.47 | 1.22 ± 0.38 | 1.56 ± 0.46 | < 0.001 |
| Knee extension endurance (J) | 826 (622, 1120) | 719 (557, 874) | 860 (638, 1138) | 0.015 |
| Dorsiflexion strength (ankle joint) (kgf) | 32 ± 8 | 29 ± 7 | 33 ± 8 | 0.001 |
| Toe pinch force (kgf) | 3.6 (2.8, 4.6) | 3.1 (2.3, 3.9) | 3.7 (3.0, 4.7) | 0.002 |
| Grip strength (kgf) | 29 (22, 37) | 23 (20, 30) | 30 (24, 38) | < 0.001 |
| Balance capability | ||||
| Index of postural stability | 1.62 (1.37, 1.82) | 1.54 (1.28, 1.77) | 1.63 (1.39, 1.84) | 0.085 |
| Modified index of postural stability | 0.17 (0.07, 0.34) | 0.15 (0.06, 0.23) | 0.18 (0.07, 0.35) | 0.187 |
| One-leg standing time (s) | 45 (15, 111) | 26 (10, 79) | 49 (18, 120) | 0.052 |
| Flexibility | ||||
| Finger-to-floor distance (cm) | –2 (–12, 6) | 0 (–9, 8) | –3 (–12, 6) | 0.175 |
Data are the mean ± SD or median (25th, 75th). MVPA, moderate-to-vigorous physical activity.
Multivariate association of fall-related variables with clinical parameters in stepwise logistic regression analysis.
| Covariates | Fallers (Adjusted R2 = 0.200) | |
|---|---|---|
| Knee extension strength | − 0.698 | 0.002 |
| Fasting C-peptide level | 0.492 | 0.009 |
| Dorsiflexion strength | − 0.432 | 0.047 |
Covariates: sex, fasting C-peptide levels, impaired vibratory sensation, presence of proliferative retinopathy, past history of stroke, taking sulfonylureas at discharge, skeletal muscle percentage, body fat percentage, knee extension strength, knee extension endurance, dorsiflexion strength, toe pinch force, grip strength, index of postural stability, and one-leg standing time.
Average importance of covariates in the random forest model.
| Covariates | Covariate importance |
|---|---|
| Grip strength | 0.495 |
| Fasting C-peptide level | 0.397 |
| Knee extension strength | 0.058 |
| Dorsiflexion strength | 0.037 |
| Presence of proliferative retinopathy | 0.011 |
Covariates: sex, fasting C-peptide levels, impaired vibratory sensation, presence of proliferative retinopathy, past history of stroke, taking sulfonylureas at discharge, skeletal muscle percentage, body fat percentage, knee extension strength, knee extension endurance, dorsiflexion strength, toe pinch force, grip strength, and index of postural stability.